Recent News

• 10.06.2025 - Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
• 10.06.2025 - Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
• 09.24.2025 - Paul B. Bolno, MD.
• 09.24.2025 - Paul B. Bolno, MD.
• 09.24.2025 - Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
• 09.24.2025 - Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
• 09.24.2025 - Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
• 09.24.2025 - Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
• 09.17.2025 - Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
• 09.17.2025 - Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Recent Filings

• 10.06.2025 - EX-99.1 EX-99.1
• 10.06.2025 - 8-K Current report
• 10.02.2025 - S-3 Registration statement under Securities Act of 1933
• 09.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.24.2025 - 3 Initial statement of beneficial ownership of securities
• 09.24.2025 - 8-K Current report
• 09.24.2025 - EX-99.1 EX-99.1
• 09.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors